Why Is ERASCA INC (ERAS) Stock Down Today?

Erasca (ERAS) shares fell 6.80% to $14.71 as the company reported third-quarter results that missed analyst expectations. The primary driver of the decline was a GAAP earnings per share figure of negative $0.15, which came in $0.01 below the consensus estimate.

What Happened

Erasca filed a Form 8-K with the Securities and Exchange Commission on November 12, 2026, disclosing its financial condition and results of operations. The company reported that cash, cash equivalents, and marketable securities totaled $947.8 million as of September 30. While the earnings miss triggered the immediate sell-off, the stock also remains in a broader downward trend. Over the last eight trading sessions, the shares have declined by 5.0%, moving from $14.78 to $14.04.

Additionally, Grabar Law Office announced it is investigating claims on behalf of long-term shareholders of Erasca, alongside several other companies. The firm is reviewing potential claims related to the company's recent disclosures. On the operational front, Erasca and Tango Therapeutics have begun enrollment in a Phase 1/2 clinical trial for vopimetostat plus ERAS-0015 in pancreatic and lung cancer.

What The Data Shows

The stock opened at $15.70, representing a 0.5% gap down from the prior close of $15.78. Intraday trading saw the price hit a session high of $15.85 at 8:00 AM ET before sliding to a session low of $14.12 at 9:35 AM ET. Volume stood at 0.5 million shares, which is 0.1 times the three-month daily average.

Fundamentally, Erasca has a market capitalization of $5.9 billion and remains unprofitable with a trailing twelve-month EPS of negative $0.97. The stock has a beta of 0.65 and trades within a 52-week range of $2.34 to $24.28. Notably, the 52-week tape recorded one fresh high and six fresh lows on November 13, 2026.

What To Watch

Investors will monitor the ongoing Phase 1/2 clinical trial with Tango Therapeutics for further updates on the vopimetostat combination. The recent legal investigation by Grabar Law Office may also influence near-term sentiment as the firm completes its review of shareholder claims.